AI-generated summary
The authors prospectively studied 27 postmenopausal women with genitourinary syndrome of menopause who received eight weekly 30-minute sessions of 660-nm vaginal photobiomodulation. They report significant improvements in vaginal health and urinary and sexual symptom scores that persisted at three months, with no adverse events observed. The study was single-center and uncontrolled, with only 13.3% reaching the sexual function cutoff at follow-up.
- Participants
- 27
- Who or what was studied
- Postmenopausal women with genitourinary syndrome of menopause (mean age 62.9 years)
- Wavelengths
- 660 nm
- Limits stated in the abstract
- The abstract describes a single-center prospective study with a small sample of 27 women and does not mention a control group.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Genitourinary syndrome of menopause (GSM) is common, and non-hormonal treatment options are needed for women unsuitable for or reluctant to use estrogen therapy.
Objective
To prospectively evaluate clinical outcomes and clinical improvement rates of photobiomodulation (PBM) for GSM.
Methods
Twenty-seven postmenopausal women with GSM were enrolled in a prospective study conducted from January 2024 to July 2025. Participants received eight weekly 30-minute sessions of pulsed 660-nm PBM delivered through a stationary silicone vaginal light-guide probe. With the probe attached, target irradiance was 32.38mW/cm² at the probe tip and 13.38mW/cm² at the probe side, corresponding to per-session radiant exposures of 29.14J/cm² at the vaginal fornix and 12.04J/cm² at the vaginal wall. Assessments occurred at baseline (V1), pre-4th session (V2), pre-8th session (V3), and three months post-treatment (V4). The primary outcome was the Vaginal Health Index (VHI). Secondary outcomes included validated questionnaires for lower urinary tract symptoms (LUTS) and sexual function (FSFI). Clinical improvement was defined using established minimal clinically important differences (MCID), minimal detectable change (MDC), and cutoff scores as thresholds.
Results
The mean age of participants was 62.9 ± 9.7 years. Total VHI scores were significantly higher at all follow-up time points compared to baseline (p < 0.05), with all participants reaching the non-atrophic VHI threshold at V4. UDI-6, IIQ-7, OABSS, and several KHQ domains improved significantly (p < 0.05) and persisted through the 3-month follow-up. Total FSFI scores improved significantly (p < 0.05), but only 13.3% reached the clinical cutoff (≥26.5) at V4 for functional recovery. No adverse events were observed during the study period.
Conclusions
Intravaginal 660-nm PBM is a well-tolerated, non-hormonal modality that may improve objective vaginal health and subjective symptoms in GSM. As an integrated therapeutic option, PBM may also improve GSM-related LUTS, suggesting potential relevance for geriatric patients with polypharmacy concerns.
Trial Registration
ClinicalTrials.gov NCT06074120.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Fluence, Minimal clinically important difference, Trial registration, Primary outcome, Irradiance. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.